hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 00:14:20 - browse：989

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： How Brent Saunders' Allergan experiment failed

hotspot

WSS

Sen. Paul opposes bill to ban Chinese biotechs

UnitedHealth quietly bought dozens of outpatient centers

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

New chief aims to remake Sanofi Genzyme

focus

hotspot

entertainment

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Medicare proposal to cover medical devices draws a mixed reaction

Hey, doctors: Don't be no

After affirmative action ruling, medical educators look to 'holistic review'

UnitedHealth quietly bought dozens of outpatient centers

In Memoriam: Notable people who died in 2023

With psoriasis trial ahead, Alumis raises $259 million

The high cost of giving birth even with insurance

Why the advice to take all your antibiotics may be wrong

Wikipedia

Prosecutors say FTX founder Sam Bankman

NEJM study link tiny plastics in blood vessels to heart problems

A former Republican legislative candidate has been charged for his role in the US Capitol riot

New chief aims to remake Sanofi Genzyme

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

CDC marks new Covid

explore

hotspot

focus

hotspot